BOSTON, May 20, 2024
/PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic
medicine company pioneering single-course epigenetic editing
therapeutics, today announced the appointment of Jenny Marlowe, Ph.D., as the Company's Chief
Development Officer. Dr. Marlowe is a seasoned biopharma executive
and scientific leader with deep expertise in translational,
preclinical development, and preclinical safety across multiple
genomic medicine modalities.
"I am thrilled to welcome Jenny to Chroma," said Catherine Stehman-Breen, M.D., CEO of Chroma.
"Jenny joins our team at a pivotal time as we prepare to transition
to the clinic. Her leadership, experience, and expertise will be
instrumental as we work to bring our most transformative epigenetic
editing medicines to patients."
Dr. Marlowe joins Chroma from Solid Biosciences (previously
AvantiBio), where she was the Chief Scientific Officer, leading
discovery, research, and translational development. Previously she
was Vice President of Preclinical and Translational Development at
bluebird bio where she served as Program Lead for Zynteglo, a now
approved gene therapy for beta thalassemia. Dr. Marlowe began her
career at Novartis, where she held multiple leadership positions
including Global Head of Strategic Planning and Communication,
Investigative Technology, and Director of Translational Safety
Models, Preclinical Safety. Dr. Marlowe holds a Ph.D. in Molecular
Toxicology, with an emphasis in cellular and molecular mechanisms
of carcinogenesis, from the Department of Environmental Health
Sciences at the University of
Cincinnati and a B.S. in Zoology from Miami University, Oxford,
Ohio and is a long-standing Diplomate of the American Board
of Toxicology.
"Chroma's epigenetic editing platform, which leverages the
cell's endogenous system to durably regulate gene expression
without cutting or nicking the DNA, is an incredibly compelling
technology for creating breakthrough medicines," said Dr. Marlowe.
"I am excited to join Chroma and eager to focus on advancing this
new class of genomic therapies to patients."
About Chroma Medicine
Chroma Medicine is a biotechnology company pioneering a new
class of genomic medicines that harnesses epigenetics, nature's
innate mechanism for gene regulation, to deliver precise,
programmable single-course therapeutics while preserving genomic
integrity. The company's modular platform enables development of
medicines that can address a wide range of complex diseases,
whether they require silencing, activation, or targeting multiple
genes at once. Chroma was founded by the world's foremost experts
in genomic research and is led by a veteran team of industry
leaders and scientists with deep experience in genomic medicine,
drug discovery, and development. For more information, please visit
chromamedicine.com or follow the company
on LinkedIn and X (formerly known as
Twitter).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chroma-medicine-announces-appointment-of-jenny-marlowe-phd-as-chief-development-officer-302150087.html
SOURCE Chroma Medicine